Longeveron Inc. (LGVN)

Market Cap	19.56M
Revenue (ttm)	2.07M
Net Income (ttm)	-18.69M
Shares Out	21.06M
EPS (ttm)	-1.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	305,069
Open	0.9200
Previous Close	0.9170
Day's Range	0.9142 - 0.9302
52-Week Range	0.6330 - 2.4840
Beta	0.15
Analysts	Strong Buy
Price Target	6.50 (+599.75%)
Earnings Date	Nov 4, 2025

About LGVN

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer’s disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 12, 2021
• Employees: 25
• Stock Exchange: NASDAQ
• Ticker Symbol: LGVN
• Website: https://longeveron.com

Financial Performance

In 2024, Longeveron's revenue was $2.39 million, an increase of 237.38% compared to the previous year's $709,000. Losses were -$24.62 million, 10.9% more than in 2023.

Analyst Summary

According to 2 analysts, the average rating for LGVN stock is "Strong Buy." The 12-month stock price target is $6.5, which is an increase of 599.75% from the latest price.

Price Target

$6.5

(599.75% upside)

Analyst Consensus: Strong Buy